JPH04320675A - Oligonucleotide for detecting enterotoxigenic escharichia coli and detection using the same oligonucleotide - Google Patents
Oligonucleotide for detecting enterotoxigenic escharichia coli and detection using the same oligonucleotideInfo
- Publication number
- JPH04320675A JPH04320675A JP8642491A JP8642491A JPH04320675A JP H04320675 A JPH04320675 A JP H04320675A JP 8642491 A JP8642491 A JP 8642491A JP 8642491 A JP8642491 A JP 8642491A JP H04320675 A JPH04320675 A JP H04320675A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleotide sequence
- coli
- primer
- primers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 20
- 230000000688 enterotoxigenic effect Effects 0.000 title abstract description 5
- 238000001514 detection method Methods 0.000 title description 17
- 241000588724 Escherichia coli Species 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 239000002773 nucleotide Substances 0.000 claims description 39
- 125000003729 nucleotide group Chemical group 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 231100000033 toxigenic Toxicity 0.000 claims description 14
- 230000001551 toxigenic effect Effects 0.000 claims description 14
- 239000000147 enterotoxin Substances 0.000 claims description 6
- 231100000655 enterotoxin Toxicity 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 101710146739 Enterotoxin Proteins 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims 1
- 230000004544 DNA amplification Effects 0.000 abstract description 6
- 206010016952 Food poisoning Diseases 0.000 abstract description 5
- 208000019331 Foodborne disease Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 2
- 239000002585 base Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000602423 Vibrio cholerae O1 Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は、臨床検査、とりわけ食
中毒にかかる検査、あるいは食品検査での易熱性腸内毒
素(LT)を産生する大腸菌の検出に関するものである
。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the detection of Escherichia coli producing heat-labile enterotoxins (LT) in clinical tests, particularly food poisoning tests or food tests.
【0002】0002
【従来の技術】検査材料が患者の嘔吐物、糞便、食品、
または拭き取り材料の場合、毒素原性大腸菌と同定する
までには、増菌培養、分離培養を経て、純培養、および
確認培養を行わなければならない。さらに引き続いて、
血清学的検査、腸内毒素産生試験、その他の生化学的試
験を行うことで、はじめて毒素原性大腸菌と同定される
。 各培養段階に要する時間は、18〜24時間であ
り、その後の検査にかかる時間を合計すると1週間もの
長時間を要する。[Prior art] Test materials include patient's vomit, feces, food,
In the case of wipes, enrichment culture, isolation culture, pure culture, and confirmation culture must be performed before identifying toxigenic E. coli. Continuing further,
It is only through serological tests, intestinal toxin production tests, and other biochemical tests that it is identified as toxigenic E. coli. The time required for each culture stage is 18 to 24 hours, and the total time required for subsequent tests requires a long time of one week.
【0003】易熱性腸内毒素(以下、LT)を検出する
目的であれば、逆受身ラテックス凝集反応を利用した腸
内毒素検出用キットも市販されているが、コレラ菌腸内
毒素(以下、CT)とLTとは互いに免疫学的に抗原共
通性を有することが知られており、このためCTとLT
とを区別して検出することが困難である。For the purpose of detecting heat-labile enterotoxin (hereinafter referred to as LT), enterotoxin detection kits using reverse passive latex agglutination reactions are commercially available; CT) and LT are known to have immunological common antigens with each other; therefore, CT and LT
It is difficult to distinguish between and detect.
【0004】また、検体としては、純培養され、さらに
、ある程度菌種の同定に関して、絞り込みが行われたも
のを必要としている。この絞り込みの段階までの操作が
煩雑であり、長時間を要する。しかも、このキットにか
かる時間だけでも20〜24時間も必要とする。[0004] In addition, the specimen needs to be pure cultured and, furthermore, must have been narrowed down to some extent to identify the bacterial species. The operations up to this stage of narrowing down are complicated and take a long time. Moreover, this kit alone requires 20 to 24 hours.
【0005】[0005]
【発明が解決しようとする課題】上記したように、従来
の方法はいずれも、毒素原性大腸菌と同定するまでには
非常に複雑な操作と長時間を要し、迅速性を要求される
臨床検査等に向かなかった。[Problems to be Solved by the Invention] As mentioned above, all of the conventional methods require extremely complicated operations and a long time to identify toxigenic E. coli. I didn't go for any tests.
【0006】一方、最近では、オリゴヌクレオチドを用
いたDNAプローブ法あるいはハイブリダイゼーション
法が試みられるようになってきた。しかし、オリゴヌク
レオチドを標識修飾したプローブにより膜上、あるいは
他の支持体上でハイブリダイゼーションを行い、これを
検出する場合、細菌検査において十分な検出感度と選択
性を得るのが難しい。On the other hand, recently, DNA probe methods or hybridization methods using oligonucleotides have been attempted. However, when hybridization is performed on a membrane or other support using a probe in which oligonucleotides are labeled and then detected, it is difficult to obtain sufficient detection sensitivity and selectivity in bacterial testing.
【0007】本発明は、オリゴヌクレオチドを核酸合成
反応のプライマーとして機能させた遺伝子増幅技術によ
り毒素原性大腸菌由来の核酸を検出するもので、簡便、
迅速かつ高感度な検出法を食中毒菌検査において提供す
ることを目的とする。[0007] The present invention detects nucleic acids derived from toxigenic Escherichia coli using gene amplification technology in which oligonucleotides function as primers for nucleic acid synthesis reactions.
The purpose is to provide a rapid and highly sensitive detection method for testing food poisoning bacteria.
【0008】[0008]
【課題を解決するための手段】本発明は、毒素原性大腸
菌由来の核酸と選択的にハイブリダイズするオリゴヌク
レオチドを作製し、このオリゴヌクレオチドをプライマ
ーとして遺伝子増幅に用い、食中毒症状を起こす毒素原
性大腸菌のみを選択的に検出することを特徴としている
。[Means for Solving the Problems] The present invention produces oligonucleotides that selectively hybridize with nucleic acids derived from toxigenic Escherichia coli, and uses these oligonucleotides as primers for gene amplification to produce toxins that cause food poisoning symptoms. It is characterized by selectively detecting only Escherichia coli.
【0009】本発明で用いるオリゴヌクレオチドは、検
体中に存在する毒素原性大腸菌の産生する易熱性腸内毒
素(heat−labile toxin, LT)遺
伝子をコードするヌクレオチド配列を標的とし、そのヌ
クレオチド配列と相補的となるように化学合成されたオ
リゴヌクレオチドであって、合成ヌクレオチドが以下の
配列群、(5’)d−CCCAGATGAAATAAA
ACGT−(3’)・・・・(a) (5’)d−CC
TGAGATATATTGTGCTC−(3’)・・・
・(b) (5’)d−ACAAACCGGCTTTG
TCAGATAT−(3’)・(c) (5’)d−G
TTATATATGTCAACCTCTGAC−(3’
)・(d) (5’)d−ACCGGTATTACAG
AAATCTGA−(3’)・・(e) または対応す
る相補的配列からなることを特徴とする。[0009] The oligonucleotide used in the present invention targets the nucleotide sequence encoding the heat-labile toxin (LT) gene produced by toxigenic Escherichia coli present in the sample, and An oligonucleotide chemically synthesized to be complementary, the synthetic nucleotides having the following sequence group, (5') d-CCCAGATGAAATAAA
ACGT-(3')...(a) (5')d-CC
TGAGATATATTGTGCTC-(3')...
・(b) (5')d-ACAAACCGGCTTTG
TCAGATAT-(3')・(c) (5')d-G
TTATATATGTCAACCTCTGAC-(3'
)・(d) (5')d-ACCGGTATTACAG
It is characterized by consisting of AAATCTGA-(3')...(e) or a corresponding complementary sequence.
【0010】ここで、遺伝子増幅は、Saiki らが
開発したPolymerase Chain Reac
tion 法(以下、略してPCR法;Science
230,1350(1985))をもとに行っている
。この方法は、ある特定のヌクレオチド配列領域(本発
明の場合は毒素原性大腸菌のLT遺伝子)を検出する場
合、その領域の両端の一方は+鎖を、他方は−鎖をそれ
ぞれ認識してハイブリダイゼーションするようなオリゴ
ヌクレオチドを用意し、それを熱変性により1本鎖状態
にした試料核酸に対し鋳型依存性ヌクレオチド重合反応
のプライマーとして機能させ、生成した2本鎖核酸を再
び1本鎖に分離し、再び、同様な反応を起こさせる。こ
の一連の操作を繰り返すことで2つのプライマーに挟ま
れた領域は検出できるまでにコピー数が増大してくる。[0010] Here, gene amplification is performed using Polymerase Chain Reac developed by Saiki et al.
tion method (hereinafter abbreviated as PCR method; Science
230, 1350 (1985)). When detecting a specific nucleotide sequence region (in the case of the present invention, the LT gene of toxigenic E. coli), this method recognizes the positive strand at one end of the region and the negative strand at the other end. Prepare an oligonucleotide that can hybridize, use it as a primer for a template-dependent nucleotide polymerization reaction against a sample nucleic acid that has been made into a single-stranded state by heat denaturation, and separate the generated double-stranded nucleic acid into single strands again. and cause the same reaction to occur again. By repeating this series of operations, the copy number of the region sandwiched between the two primers increases to the point where it can be detected.
【0011】検体としては、臨床検査材料、例えば、糞
便、尿、血液、組織ホモジェネートなど、また、食品材
料でもよい。The specimen may be clinical test materials such as feces, urine, blood, tissue homogenate, etc., or food materials.
【0012】これら材料をPCRの試料として用いるに
は、材料中に存在する菌体から核酸成分を遊離させる操
作が前処理として必要となる。しかし、プライマーがハ
イブリダイズできる核酸が数分子から数十分子以上存在
すればPCRは進むので、検査材料を溶菌酵素、界面活
性剤、アルカリ等で短時間処理するだけでPCRを進行
させるに十分な核酸量を持った試料液が調製できる。[0012] In order to use these materials as samples for PCR, an operation to release nucleic acid components from bacterial cells present in the materials is required as a pretreatment. However, PCR will proceed if there are several to tens of molecules of nucleic acids that can be hybridized with the primers, so a short treatment of the test material with lytic enzyme, surfactant, alkali, etc. is sufficient for PCR to proceed. A sample solution with a certain amount of nucleic acid can be prepared.
【0013】本発明でプライマーとして用いられるオリ
ゴヌクレオチドは、選択性や検出感度および再現性から
考えて、10塩基以上、望ましくは15塩基以上の長さ
を持ったヌクレオチド断片で、化学合成あるいは天然の
どちらでもよい。また、プライマーは、特に検出用とし
て標識されていなくてもよい。The oligonucleotide used as a primer in the present invention is a nucleotide fragment having a length of 10 bases or more, preferably 15 bases or more, and is either chemically synthesized or natural, in terms of selectivity, detection sensitivity, and reproducibility. either will do. Further, the primer does not need to be specifically labeled for detection.
【0014】プライマーが規定している腸炎ビブリオ菌
の特定遺伝子のヌクレオチド配列における増幅領域は、
50塩基から2,000塩基、望ましくは、100塩基
から1,000塩基となればよい。[0014] The amplified region in the nucleotide sequence of the specific gene of Vibrio parahaemolyticus defined by the primer is
The number may be from 50 bases to 2,000 bases, preferably from 100 bases to 1,000 bases.
【0015】鋳型依存性ヌクレオチド重合反応には、耐
熱性DNAポリメラーゼを用いているが、この酵素の起
源については90〜95℃、プライマーをハイブリダイ
ズさせるアニーリング操作の温度は37〜65℃、重合
反応は50〜75℃で、これを1サイクルとしたPCR
を20から42サイクル行って増幅させる。[0015] A thermostable DNA polymerase is used in the template-dependent nucleotide polymerization reaction, but the origin of this enzyme is 90-95°C, the temperature of the annealing operation for hybridizing the primers is 37-65°C, and the temperature of the polymerization reaction is 90-95°C. PCR was performed at 50-75°C, with this as one cycle.
is carried out for 20 to 42 cycles for amplification.
【0016】検出はPCRを終えた反応液をそのままア
ガロースゲル電気泳動にかけることで、増幅されたヌク
レオチド断片の存在、およびその長さが確認できる。そ
の結果から、検体中にプライマーが認識すべき配列を持
ったヌクレオチドが存在しているかどうか判定すること
ができる。この判定は、そのままLTを産出する大腸菌
の有無を判定するものとなる。増幅されたヌクレオチド
断片の検出には、その他の電気泳動やクロマトグラフィ
ー、DNAプロ−ブ法も有効である。[0016] For detection, the presence of the amplified nucleotide fragment and its length can be confirmed by directly subjecting the reaction solution after PCR to agarose gel electrophoresis. From the results, it can be determined whether a nucleotide with a sequence that the primer should recognize exists in the sample. This determination determines the presence or absence of E. coli that can directly produce LT. Other methods such as electrophoresis, chromatography, and DNA probe methods are also effective for detecting amplified nucleotide fragments.
【0017】[0017]
【作用】本発明は、オリゴヌクレオチドを核酸合成反応
のプライマーとして機能させた遺伝子増幅技術により毒
素原性大腸菌由来のLTを検出するもので、簡便、迅速
かつ高感度な検出ができる。[Operation] The present invention detects LT derived from toxigenic Escherichia coli using gene amplification technology in which oligonucleotides function as primers for nucleic acid synthesis reactions, and enables simple, rapid and highly sensitive detection.
【0018】[0018]
【実施例】(実験例1)検体の調製
毒素原性大腸菌の検索には、表1〜表13の縦の見出し
に示した下痢症患者から分離した大腸菌492株を用い
た。これらの菌株は京都大学医学部微生物学教室(主任
、竹田美文教授)から分与された。それぞれの菌株を適
当な増菌培地に接種し、37 ℃、好気的条件下で終
夜培養を行い、その培地1. 5mlから遠心操作によ
り菌体を回収した。10mmトリス−塩酸緩衝液(pH
7. 5)で1回洗浄後、同緩衝液にリゾチームを1m
g/mlとなるように溶かした液0. 5mlで懸濁さ
せ、37 ℃、10分で溶菌させた。前記緩衝液で飽
和させたフェノールおよびクロロフォルムからなる混合
液(混合比1:1)を溶菌液に加え、よく撹はんした。
遠心後、上層液を回収し、エタノール処理を行って、核
酸成分を沈澱させた。その沈澱物を前記緩衝液1mlに
溶かして、これを検体とした。EXAMPLES (Experimental Example 1) Preparation of Samples For searching for toxigenic E. coli, 492 strains of E. coli isolated from patients with diarrhea shown in the vertical headings of Tables 1 to 13 were used. These strains were provided by the Department of Microbiology, Faculty of Medicine, Kyoto University (head: Professor Yoshifumi Takeda). Each strain was inoculated into an appropriate enrichment medium and cultured overnight at 37°C under aerobic conditions. Bacterial cells were collected from 5 ml by centrifugation. 10 mm Tris-HCl buffer (pH
7. After washing once with 5), add 1 m of lysozyme to the same buffer.
The solution was dissolved to give a concentration of 0.g/ml. The cells were suspended in 5 ml and lysed at 37°C for 10 minutes. A mixture of phenol and chloroform (mixing ratio 1:1) saturated with the buffer was added to the lysate and stirred well. After centrifugation, the supernatant liquid was collected and treated with ethanol to precipitate nucleic acid components. The precipitate was dissolved in 1 ml of the above buffer solution and used as a sample.
【0019】プライマーの合成
易熱性腸内毒素を産生する大腸菌のLT遺伝子の塩基配
列(Yamamoto,T., T.Tamura a
nd T.Yokota (1984):Primar
y structure of heat−labil
e enterotoxin produced by
Eschelichia coli pathoge
nic for humans. J. Biol.
Chem., 259:5037−5044 および
Yamamoto, T., T.Gojobori
and T.Yokota (1987):Evol
utionary origin of pathog
enic determinants in ente
rotoxigenic Eshelichia co
liand Vibrio cholerae O1.
J. Bateriol., 169:1352−1
357 )から請求項第1項に示した配列((a) 、
(b) 、(c) 、(d) 、および(e) )を選
び、それと同じ配列を持つオリゴヌクレオチドを化学合
成した。化学合成はサイクロンプラスDNA合成装置(
ミリジェン/バイオリサーチ社製)を用い、β−シアノ
エチルフォスホアミダイト法により行った。合成したオ
リゴヌクレオチドの精製はC18逆相カラムを用いた高
速液体クロマトグラフィーで行った。Synthesis of primers Base sequence of the LT gene of Escherichia coli that produces heat-labile enterotoxin (Yamamoto, T., T. Tamura a
nd T. Yokota (1984): Primar
y structure of heat-labile
e enterotoxin produced by
Escherichia coli pathway
nic for humans. J. Biol.
Chem. , 259:5037-5044 and Yamamoto, T. , T. Gojobori
and T. Yokota (1987): Evol.
utionary origin of pathog
enic determinants in ente
rotoxigenic Eshelichia co
liand Vibrio cholerae O1.
J. Bateriol. , 169:1352-1
357) to the sequence shown in claim 1 ((a),
(b), (c), (d), and (e)), and oligonucleotides having the same sequences were chemically synthesized. Chemical synthesis is performed using Cyclone Plus DNA Synthesizer (
Milligen (manufactured by Bioresearch) was used, and the β-cyanoethyl phosphoramidite method was used. The synthesized oligonucleotide was purified by high performance liquid chromatography using a C18 reverse phase column.
【0020】PCR
前記検体液3μlを用い、それに滅菌水16. 05μ
l、10x反応用緩衝液3μl、dNTP溶液4. 8
μl、プライマー(1 )1. 5μl、プライマー(
2 )1. 5μl、および耐熱性DNAポリメラーゼ
0. 15μlを加えて30μlの反応液を調製した。
この反応液の入った容器にミネラルオイル(SIGMA
社製)を50μl加え、反応液上に重層した。各添加
された液の内容、およびプライマー(1 )と(2 )
の組合せを下記に示す。[0020] PCR Using 3 μl of the above sample solution, add 16.0 μl of sterile water to it. 05μ
1, 3 μl of 10x reaction buffer, dNTP solution 4. 8
μl, primer (1) 1. 5 μl, primer (
2)1. 5 μl, and 0.0 μl of thermostable DNA polymerase. 15 μl was added to prepare a 30 μl reaction solution. Add mineral oil (SIGMA) to the container containing this reaction solution.
50 µl of 50 μl of 100% of the reaction mixture was added and layered on top of the reaction solution. Contents of each added solution and primers (1) and (2)
The combinations are shown below.
【0021】
10x反応緩衝液: 500mM KCl, 10
0mM Tris−HCl(pH8.3), 15mM
MgCl2 ,
0.1% (W/V) ゼラチン dNT
P溶液: dATP, dCTP, dGTP, dT
TP を混合させたもので各終濃度が
1.25mM プライマー
(1 )および(2 ): 前述した化学合成精製品の
各水溶液
(濃度 5 ODU/
ml)プライマーの組合せ:前述の化学合成精製品で次
のとおりに3組つくり、実験に用いた。
反応条件は、次のとおりである。10x reaction buffer: 500mM KCl, 10
0mM Tris-HCl (pH 8.3), 15mM
MgCl2,
0.1% (W/V) Gelatin dNT
P solution: dATP, dCTP, dGTP, dT
The final concentration of each mixture is
1.25mM Primers (1) and (2): Each aqueous solution of the chemically synthesized purified product mentioned above
(Concentration 5 ODU/
ml) Combination of primers: Three sets of primers were prepared as follows using the chemically synthesized purified product described above and used in the experiment. The reaction conditions are as follows.
【0022】熱変性:94 ℃、1分アニーリング:
55 ℃、1分
重合反応:72 ℃、1分
熱変性からアニーリングを経て重合反応に至る過程を1
サイクル(所要時間5.7 分)とし、これを35サイ
クル(総所要時間約3時間)行った。これらの操作は、
DNAサーマルサイクラー(Perkin Elmer
Cetus社製)に上記反応条件をプログラムするこ
とにより行った。Heat denaturation: 94°C, 1 minute annealing:
55 ℃, 1 minute polymerization reaction: 72 ℃, 1 minute The process from thermal denaturation to annealing to polymerization reaction is 1.
35 cycles (total time required: about 3 hours). These operations are
DNA thermal cycler (Perkin Elmer
(manufactured by Cetus) by programming the above reaction conditions.
【0023】検出
反応液から、増幅されたヌクレオチド断片を検出するた
め、アガロースゲル電気泳動を以下のように行った。Detection In order to detect the amplified nucleotide fragments from the reaction solution, agarose gel electrophoresis was performed as follows.
【0024】アガロースゲルはゲル濃度3%(W/V
)とし、臭化エチジウム(0.5 μl/ml)を含む
ものを用いた。泳動の電気的条件は、定電圧100V、
30分で行った。操作方法ならびに他の条件は、Man
iatis等著Molecular Cloning(
1982) に記載されている技法で行った。
反応液の他に分子量マーカーの泳動も同時に行い、相対
移動度の比較により、ヌクレオチド断片の長さを算出し
た。[0024] The agarose gel has a gel concentration of 3% (W/V
) containing ethidium bromide (0.5 μl/ml). The electrical conditions for electrophoresis were a constant voltage of 100V,
It took 30 minutes. For operating methods and other conditions, please refer to Man
Molecular Cloning by Iatis et al.
This was done using the technique described in (1982). In addition to the reaction solution, a molecular weight marker was also run at the same time, and the length of the nucleotide fragment was calculated by comparing the relative mobility.
【0025】結果
前述したように、LT遺伝子は、既に塩基配列が決定さ
れており、本発明のオリゴヌクレオチオド、すなわちプ
ライマーがPCRにより増幅させてくるヌクレオチドの
大きさは推定できる。それによると、プライマー(a
)と(b )、(c)と(d )、および(e )と(
d )の各組を用いた場合には、それぞれ589、55
0および264塩基の長さのヌクレオチドが増幅されて
くるはずである。これらの推定値と増幅されたヌクレオ
チドの長さが一致した場合、各プライマーはLT遺伝子
の標的としている領域を正しく増幅していると判断した
。大腸菌の臨床分離株492株を上記方法で検討し、増
幅されてきたヌクレオチドの長さを測定した結果を表1
〜表13に示す。表1〜表13プライマー(prime
r)欄中、+と記入されたものは、増幅されてきたヌク
レオチドの長さが推定値と一致したもの、また−は増幅
ヌクレオチドが全く検出されなかったものである。Results As mentioned above, the nucleotide sequence of the LT gene has already been determined, and the size of the oligonucleotides of the present invention, ie, the nucleotides amplified by the primers by PCR, can be estimated. According to it, primer (a
) and (b), (c) and (d), and (e) and (
d), 589 and 55, respectively.
Nucleotides of length 0 and 264 bases should be amplified. When these estimated values and the length of the amplified nucleotides matched, it was determined that each primer was correctly amplifying the targeted region of the LT gene. Table 1 shows the results of examining 492 clinical isolates of E. coli using the above method and measuring the length of the amplified nucleotides.
- Shown in Table 13. Tables 1 to 13 Primers (prime
In the r) column, + indicates that the length of the amplified nucleotide matched the estimated value, or - indicates that no amplified nucleotide was detected.
【0026】同表で示されるように、各組合せのプライ
マーでPCRを行うと、どれも、LT遺伝子を有する菌
株(表1〜表13のLTgene欄が+、2+、および
wのもの)においてのみ、ヌクレオチドを増幅させてい
る。
しかも、増幅されたヌクレオチドのすべては、推定され
たヌクレオチドの長さと一致している。したがって、本
発明のオリゴヌクレオチド、すなわちプライマーは毒素
原性大腸菌のLT遺伝子の標的としている領域を正しく
増幅していることが明らかである。[0026] As shown in the same table, when PCR was performed with each combination of primers, only strains having the LT gene (those with +, 2+, and w in the LTgene column in Tables 1 to 13) , amplifying nucleotides. Moreover, all of the amplified nucleotides are consistent with the predicted nucleotide length. Therefore, it is clear that the oligonucleotides, ie, the primers of the present invention, correctly amplify the targeted region of the LT gene of toxigenic E. coli.
【0027】(実験例2)実験例1で得られた結果が、
LTを産生する大腸菌に対して選択的なものかどうかを
確かめるため、臨床検査において病原大腸菌以外で検査
対象となりうる菌種について比較検討した。(Experimental Example 2) The results obtained in Experimental Example 1 are as follows:
In order to confirm whether it is selective for LT-producing E. coli, we conducted a comparative study of bacterial species other than pathogenic E. coli that can be tested in clinical tests.
【0028】方法は、実験例1に示したものと同じであ
るが、Clostridium perfringen
s 、Campylobacter jejuni、
Campylobacter coli 、Bacte
roides flagilis、Bacteroid
es vulgatus、 およびLactobac
illus acidophilus については
嫌気的条件下、37 ℃Cで終夜培養を行い、PCR
法に適用しうる試料を調製した。検体の調製において培
養した菌は、表14、15の縦の見出しに示した50菌
株である。また、ヒト胎盤由来DNA(Human p
lacenta DNA)は1μg/mlの濃度のもの
を調製し、これも同様にPCRを行わせた。The method was the same as that shown in Experimental Example 1, except that Clostridium perfringen
s, Campylobacter jejuni,
Campylobacter coli, Bacte
roides flagilis, Bacteroides
es vulgatus, and Lactobacillus
For Illus acidophilus, culture was performed overnight at 37°C under anaerobic conditions, and PCR was performed.
Samples applicable to the method were prepared. The 50 bacterial strains shown in the vertical headings of Tables 14 and 15 were cultured in the preparation of the specimens. In addition, human placenta-derived DNA (Human p
lacenta DNA) was prepared at a concentration of 1 μg/ml, and PCR was also performed on this in the same manner.
【0029】結果を表14、15に示す。各組合せのプ
ライマーでPCRを行ったが、3組のどのプライマーを
使用した場合についても、病原大腸菌以外の各種細菌の
DNAを増幅することはなかった。したがって、本発明
のオリゴヌクレオチド、すなわちプライマーは、易熱性
毒素産生性の大腸菌にのみ、選択的に反応するものと断
言できる。The results are shown in Tables 14 and 15. PCR was performed using each combination of primers, but no matter which of the three sets of primers was used, DNA of various bacteria other than pathogenic E. coli was not amplified. Therefore, it can be concluded that the oligonucleotide, ie, the primer, of the present invention selectively reacts only with heat-labile toxin-producing E. coli.
【0030】一方、本発明では、CT産生性のVibr
io cholerae (表15中、V.chole
raeO1ctx+ )とは全く交叉反応を起こさない
こともわかる。前述したように免疫学的にはCTとLT
とは抗原共通性をもっていて免疫学的手法によっても、
これらを区別することができなかった。しかし、本発明
ではLT産生性大腸菌のみを明確に検出することから、
従来法に比べて信頼性がより高くなったと考えられる。On the other hand, in the present invention, CT-producing Vibr
io cholerae (in Table 15, V. cholerae
It can also be seen that no cross-reaction occurs with raeO1ctx+). As mentioned above, immunologically, CT and LT
They have common antigens and can be detected by immunological methods.
I couldn't tell them apart. However, since the present invention clearly detects only LT-producing E. coli,
It is considered that the reliability is higher than that of the conventional method.
【0031】なお、本発明の実施例で用いているアガロ
ース電気泳動を前述の泳動条件で行えば、100塩基対
以下のヌクレオチドであれば、5から10塩基対、10
0から500塩基の範囲のヌクレオチドであれば、10
から20塩基対のヌクレオチドの長さの違いを区別可能
である。さらに、アクリルアミドなどをゲルに用いるこ
とで、ヌクレオチドの長さの測定精度を向上させること
ができ、LT遺伝子の選択的検出における信頼度は、さ
らに高まるものと考えられる。Note that if the agarose electrophoresis used in the examples of the present invention is performed under the above-mentioned electrophoresis conditions, if the nucleotide is 100 base pairs or less, 5 to 10 base pairs, 10
For nucleotides ranging from 0 to 500 bases, 10
A difference in length of 20 base pairs of nucleotides can be distinguished. Furthermore, by using acrylamide or the like in the gel, the accuracy of measuring nucleotide length can be improved, and it is thought that the reliability in selective detection of the LT gene will further increase.
【0032】[0032]
【表1】[Table 1]
【0033】[0033]
【表2】[Table 2]
【0034】[0034]
【表3】[Table 3]
【0035】[0035]
【表4】[Table 4]
【0036】[0036]
【表5】[Table 5]
【0037】[0037]
【表6】[Table 6]
【0038】[0038]
【表7】[Table 7]
【0039】[0039]
【表8】[Table 8]
【0040】[0040]
【表9】[Table 9]
【0041】[0041]
【表10】[Table 10]
【0042】[0042]
【表11】[Table 11]
【0043】[0043]
【表12】[Table 12]
【0044】[0044]
【表13】[Table 13]
【0045】[0045]
【表14】[Table 14]
【0046】[0046]
【表15】[Table 15]
【0047】なお、表中
LTgeneの欄(+):LT遺伝子を保
有する 同 (
2+): LT遺伝子を保有する 同
(w): LT遺伝子を保有す
る 同 (−)
:LT遺伝子を保有しない Primer欄
(+):増幅されたヌクレオチドの長
さが推定値と一致
したもの
同 (w):増幅されたヌクレ
オチドの長さが推定値と一致
しているが、増
幅程度が少々弱いもの 同
(−):増幅ヌクレオチドが全くみとめら
れなかったも
の表1〜13における各菌株の
入手先:京都大学医学部微生物学教室
表14、15(No.1〜39) における各菌株の入
手先:ATCC(American Type Cul
ture Collection)JCM(理化学研究
所微生物系統保存施設)IFO(発酵研究所)
表15(No.41 〜50) における菌株の入手先
:京都大学医学部微生物学教室
表15(No.51)における菌株の入手先:宝酒造株
式会社[0047] In the table, the LTgene column (+):
2+): Carrying the LT gene
(w): Same as possessing LT gene (-)
:Does not have LT gene Primer column (+): Length of amplified nucleotide matches estimated value
What I did
Same (w): The length of the amplified nucleotide matches the estimated value.
However, the degree of amplification is slightly weaker.
(−): No amplified nucleotides were observed.
Where to obtain each bacterial strain in Tables 1 to 13: Kyoto University School of Medicine Microbiology Department Where to obtain each bacterial strain in Tables 14 and 15 (No. 1 to 39): ATCC (American Type Cul
ture Collection) JCM (RIKEN Microbial System Collection Facility) IFO (Fermentation Research Institute) Sources of bacterial strains in Table 15 (No. 41 to 50): Kyoto University School of Medicine Microbiology Department Table 15 (No. 51) Source: Takara Shuzo Co., Ltd.
【0048】[0048]
【効果】本発明ではPCR法を用いたことで、毒素原性
大腸菌の検出において、遺伝子増幅作用による高い検出
感度と、2つあるいは、それ以上のプライマーで反応が
規定されることによる高い選択性を得ることができる。[Effect] By using the PCR method in the present invention, in the detection of toxigenic E. coli, high detection sensitivity due to gene amplification effect and high selectivity due to the reaction being defined by two or more primers. can be obtained.
【0049】また、高い検出感度のため多量の検体を必
要とせず、検体の前処理が簡便で済む。しかも、反応時
間が短く、検出も簡単な機材で済み、操作も容易なため
同定までの時間を大幅に短縮できる。例えば、実施例で
は、反応時間が約3時間、検出にかかる操作が30分で
ある。Furthermore, due to the high detection sensitivity, a large amount of specimen is not required, and pretreatment of the specimen is simple. Moreover, the reaction time is short, detection requires simple equipment, and operation is easy, so the time required for identification can be significantly shortened. For example, in Examples, the reaction time is approximately 3 hours, and the detection operation is 30 minutes.
【0050】また、検出にアガロースゲル電気泳動と臭
化エチジウムによる核酸染色法を用いることで、プライ
マー等を標識せずに検出が行え、しかも、核酸の長さが
確認できるので、結果の信頼性が高いものとなる。[0050] Furthermore, by using agarose gel electrophoresis and nucleic acid staining with ethidium bromide for detection, detection can be performed without labeling primers, etc. Furthermore, since the length of the nucleic acid can be confirmed, the reliability of the results is increased. becomes high.
【0051】食中毒原因菌としての病原大腸菌を同定す
る際、LTを産生しているかどうかの確認が重要となっ
ている。他の生物種でLT産生能を持つものはないこと
から、プライマーが標的とするヌクレオチド配列にLT
遺伝子を用いることで、病原大腸菌の選択的検出が可能
となる。[0051] When identifying pathogenic Escherichia coli as a food poisoning bacterium, it is important to confirm whether it produces LT. Since no other species has the ability to produce LT, the nucleotide sequence targeted by the primer contains LT.
By using genes, selective detection of pathogenic E. coli becomes possible.
【0052】[0052]
Claims (2)
る易熱性腸内毒素(heat−labile toxi
n, LT)遺伝子をコードするヌクレオチド配列を
標的とし、そのヌクレオチド配列と相補的となるように
化学合成されたオリゴヌクレオチドであって、合成ヌク
レオチドが以下の配列群、 (5’)d−CCCAGATGAAATAAAACGT
−(3’)・・・・(a) (5’)d−CCTGAG
ATATATTGTGCTC−(3’)・・・・(b)
(5’)d−ACAAACCGGCTTTGTCAG
ATAT−(3’)・(c) (5’)d−GTTAT
ATATGTCAACCTCTGAC−(3’)・(d
) (5’)d−ACCGGTATTACAGAAAT
CTGA−(3’)・・(e) または対応する相補的
配列からなることを特徴とするオリゴヌクレオチド。Claim 1: Heat-labile enterotoxin produced by toxigenic Escherichia coli present in a specimen.
n, LT) An oligonucleotide that targets a nucleotide sequence encoding a gene and is chemically synthesized to be complementary to the nucleotide sequence, the synthetic nucleotides having the following sequence group: (5') d-CCCAGATGAAATAAAACGT
-(3')・・・(a) (5')d-CCTGAG
ATATATTGTGCTC-(3')...(b)
(5')d-ACAAACCGGCTTTGTCAG
ATAT-(3')・(c) (5')d-GTTAT
ATATGTCAAACCTCTGAC-(3')・(d
) (5')d-ACCGGTATTACAGAAAT
An oligonucleotide characterized by consisting of CTGA-(3')...(e) or a corresponding complementary sequence.
なくとも1つを有するオリゴヌクレオチドを鎖長反応の
プライマーとして機能させ、標的ヌクレオチド配列を選
択的に増幅させることを特徴とする方法であって、(a
) 検体中の1本鎖状態の標的ヌクレオチド配列にプラ
イマーをハイブリダイズさせ4種のヌクレオチドの重合
反応により鎖長反応を行わせ、(b) 得られた2本鎖
標的ヌクレオチド配列を1本鎖に分離した場合、その相
補鎖は他方のプライマーによる鎖長反応の鋳型として機
能し、(c) これら2種のプライマーによる同時の鎖
長反応、プライマー鎖長生成物の鋳型からの分離、そし
て新たなプライマーによるハイブリダイゼーションを繰
り返すことにより特定のヌクレオチド配列が増幅され、
この増幅されたヌクレオチド断片を検出し、(d) そ
の結果、前記検体中に認識されるべき配列が存在してい
るか否かを判定することで毒素原性大腸菌の検出を行う
ことを特徴とする毒素原性大腸菌の検出方法。2. A method comprising selectively amplifying a target nucleotide sequence by causing an oligonucleotide having at least one of the sequences set forth in claim 1 to function as a primer for a chain length reaction. and (a
) A primer is hybridized to the single-stranded target nucleotide sequence in the sample to perform a chain length reaction by polymerization reaction of four types of nucleotides, and (b) the obtained double-stranded target nucleotide sequence is converted into a single-stranded one. If separated, the complementary strand serves as a template for a length reaction by the other primer, and (c) simultaneous length reactions by these two primers, separation of the primer length product from the template, and generation of a new By repeating hybridization with primers, a specific nucleotide sequence is amplified,
The method is characterized in that toxigenic E. coli is detected by detecting this amplified nucleotide fragment, and (d) determining whether or not the sequence to be recognized is present in the sample as a result. Method for detecting toxigenic E. coli.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3086424A JPH07114720B2 (en) | 1991-04-18 | 1991-04-18 | Oligonucleotide for detection of toxigenic Escherichia coli and detection method using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3086424A JPH07114720B2 (en) | 1991-04-18 | 1991-04-18 | Oligonucleotide for detection of toxigenic Escherichia coli and detection method using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04320675A true JPH04320675A (en) | 1992-11-11 |
JPH07114720B2 JPH07114720B2 (en) | 1995-12-13 |
Family
ID=13886516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3086424A Expired - Lifetime JPH07114720B2 (en) | 1991-04-18 | 1991-04-18 | Oligonucleotide for detection of toxigenic Escherichia coli and detection method using the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH07114720B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0556504A2 (en) * | 1992-02-18 | 1993-08-25 | Shimadzu Corporation | Oligonucleotides for detecting bacteria |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02249499A (en) * | 1989-03-24 | 1990-10-05 | Fujisawa Pharmaceut Co Ltd | Oligonucleotide for determination of species of vibrio anguillarum and pasturella piscicida and use thereof |
-
1991
- 1991-04-18 JP JP3086424A patent/JPH07114720B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02249499A (en) * | 1989-03-24 | 1990-10-05 | Fujisawa Pharmaceut Co Ltd | Oligonucleotide for determination of species of vibrio anguillarum and pasturella piscicida and use thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0556504A2 (en) * | 1992-02-18 | 1993-08-25 | Shimadzu Corporation | Oligonucleotides for detecting bacteria |
EP0556504A3 (en) * | 1992-02-18 | 1994-05-18 | Shimadzu Corp | Oligonucleotides for detecting bacteria |
EP1085100A1 (en) * | 1992-02-18 | 2001-03-21 | Shimadzu Corporation | Oligonucleotides for detecting bacteria |
Also Published As
Publication number | Publication date |
---|---|
JPH07114720B2 (en) | 1995-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0556504B1 (en) | Oligonucleotides for detecting Vibrio parahaemolyticus | |
EP1036846A2 (en) | Oligonucleotides for detecting bacteria and detection process | |
JP2792462B2 (en) | Oligonucleotides for detection of Salmonella spp. And detection methods using the same | |
JP2775663B2 (en) | Oligonucleotides for bacterial detection and detection methods using them | |
US6165724A (en) | Oligonucleotides for detecting enteric hemorrhagic E.coli and detection method using the same | |
JP2001095576A (en) | Method for detecting intestinal hemorrhagic strain of escherichia coli | |
JPH04320675A (en) | Oligonucleotide for detecting enterotoxigenic escharichia coli and detection using the same oligonucleotide | |
JPH04293486A (en) | Oligonucleotide for detecting bacterium and detecting method using same nucleotide | |
JP3141976B2 (en) | Oligonucleotides for detection of Shigella and detection methods using them | |
JP3134907B2 (en) | Oligonucleotide for detecting Vibrio cholerae and detection method using the same | |
JPH11332600A (en) | Oligonucleotide for detecting enteropathogenic escherichia colt 0157 and detection using the same | |
JPH03112498A (en) | Oligonucleotide for detecting campylobacter jejuni and detection using the same oligonucleotide | |
JP2993314B2 (en) | Oligonucleotides for detection of Staphylococcus aureus and detection methods using them | |
JP3331977B2 (en) | Oligonucleotides for detection of Shigella and detection methods using them | |
JP2885081B2 (en) | Oligonucleotide for detecting enterotoxin-producing C. perfringens and detection method using the same | |
JPH119281A (en) | Oligonucleotide for detecting bacteria and process utilizing the same | |
JPH07236500A (en) | Oligonucleotide for detection of microorganism of genus salmonella and detection method using the oligonucleotide | |
JPH0349697A (en) | Oligonucleotide for detecting bacteria and method for detection using the same | |
JPH03112497A (en) | Oligonucleotide for detecting pathogenic escherichia coli and detection using the same oligonucleotide | |
JPH05227999A (en) | Oligonucleotide for detecting enterotoxigenic escherichia coli and detection method | |
JPH0789958B2 (en) | Oligonucleotide for detection of Salmonella and detection method using the same | |
JPH03112499A (en) | Oligonucleotide for detecting thermostable toxicogenic pathogenic escherichia coli and detection using the same oligonucleotide | |
JPH11239484A (en) | Oligonucleotide for detection of clostridium perfringens and its detection using the same | |
JPH05317098A (en) | Oligonucleotide for detecting staphylococcus aureus and detection method using the same | |
JPH11332598A (en) | Oligonucleotide for detecting verocytotoxin-producing escherichia coli and detection using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071213 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081213 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091213 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091213 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101213 Year of fee payment: 15 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111213 Year of fee payment: 16 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111213 Year of fee payment: 16 |